Cargando…

Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban

Portal vein thrombosis (PVT) while using an angiogenesis inhibitor is relatively rare. A 70-year-old Asian man was diagnosed with PVT two months after initiating 5-fluorouracil/leucovorin, irinotecan, and bevacizumab therapy for rectal cancer with liver metastases. Because the metastases were small...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujiwara, Yu, Yamaguchi, Takeshi, Nakane, Minoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835470/ https://www.ncbi.nlm.nih.gov/pubmed/32788527 http://dx.doi.org/10.2169/internalmedicine.5456-20

Ejemplares similares

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2018)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
por: Lièvre, Astrid, et al.
Publicado: (2009)

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2019)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)
por: El-Deiry, Wafik S., et al.
Publicado: (2019)

Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer
por: Formica, Vincenzo, et al.
Publicado: (2017)

Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
por: Devaux, Madeline, et al.
Publicado: (2019)

A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab
por: Kanamaru, Tomohiro, et al.
Publicado: (2014)

Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

Idiopathic pulmonary vein thrombosis treated with apixaban
por: Ngo, Dallis, et al.
Publicado: (2021)

Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer
por: Mehrzad, Valiollah, et al.
Publicado: (2016)

A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer
por: Zhao, Zhifei, et al.
Publicado: (2017)

Portal Vein Thrombosis
por: Cohen, Ronny, et al.
Publicado: (2015)

A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
por: López, R, et al.
Publicado: (2010)

Metastatic Colorectal Cancer Treated with Herbal Pharmacopuncture during FOLFIRI Chemotherapy: A Case Report
por: Lee, Jung-Woo, et al.
Publicado: (2014)

Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis
por: Xu, Wei, et al.
Publicado: (2016)

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2011)

Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Efficacy and safety of FOLFIRI and biotherapy versus FOLFIRI alone for metastatic colorectal cancer patients: A meta-analysis
por: Jiang, Yangbo, et al.
Publicado: (2017)

Melioidosis with Portal Vein Thrombosis
por: Direksunthorn, Thanyaporn
Publicado: (2017)

Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
por: Fischer, Laura E., et al.
Publicado: (2022)

Balanitis associated with FOLFIRI chemotherapy
por: Micevic, Goran, et al.
Publicado: (2017)

FOLFIRI(®) and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms
por: Bécouarn, Yves, et al.
Publicado: (2014)

Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
por: Loupakis, Fotios, et al.
Publicado: (2013)

FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping
por: Yeh, Yung-Sung, et al.
Publicado: (2014)

A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab
por: Chang, Tsung-Kun, et al.
Publicado: (2021)

Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies
por: Sira, Lívia, et al.
Publicado: (2023)

Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab
por: Tanaka, Toshimitsu, et al.
Publicado: (2022)

Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study
por: Iwasa, Satoru, et al.
Publicado: (2023)

Chemotherapy for Liver Metastasis Originating from Colorectal Cancer with Portal Vein Tumor Thrombosis: A Case Report
por: Kawasaki, Atsushi, et al.
Publicado: (2013)

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
por: Carola, Candice, et al.
Publicado: (2018)

Portal bifurcation reconstruction using own hepatic vein grafts due to portal vein anomaly of the living donor for the patient with portal vein thrombosis
por: Umemura, Akira, et al.
Publicado: (2020)

Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis
por: Chen, Ke, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
por: Han, Jiaqi, et al.
Publicado: (2020)

A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
por: Liu, Yuguo, et al.
Publicado: (2015)

Spontaneous Resolution of Portal Vein Thrombosis
por: Banumukala, Vishnu, et al.
Publicado: (2008)

Etiology and Complications of Portal Vein Thrombosis
por: Trebicka, Jonel, et al.
Publicado: (2014)

Management of Portal/Mesenteric Vein Thrombosis
por: Kalff, Jörg C., et al.
Publicado: (2014)

Idiopathic Thrombosis of the Portal and Contributory Veins
por: Rogers, Bertram M. H.
Publicado: (1899)

Portal vein thrombosis in patients with cirrhosis
por: von Köckritz, Leona, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_seft9ftviau7h0jc855so99af9